Video

Dr. Salem on the FDA Approval of Y-90 Glass Microspheres for HCC

Author(s):

Riad Salem, MD, discusses the FDA approval of TheraSphere™ Yttrium-90 Glass Microsphere in March 2021 for the treatment of patients with hepatocellular carcinoma.

Riad Salem, MD, vice chair for Image Guided Therapy, Department of Radiology, chief of Vascular and Interventional Radiology in the Department of Radiology, and professor of Radiology (Vascular and Interventional Radiology), Medicine (Hematology and Oncology) and Surgery (Organ Transplantation) at the Feinberg School of Medicine, discusses the FDA approval of TheraSphere™ Yttrium-90 (Y-90) Glass Microsphere in March 2021 for the treatment of patients with hepatocellular carcinoma (HCC).

The approval stems from a collaboration between investigators, regulators, and the industry to generate a multicenter dataset that had demonstrated compelling outcomes, Salem says; these outcomes were strong enough to lead to approval of this approach. The regulatory decision possesses the potential to make Y-90 more widely available as a treatment option in more cancer centers, Salem notes.

Patients will benefit from having increased treatment options, Salem adds. Additionally, the approval of Y-90 is something that can be implemented in not only high-volume, highly specialized cancer centers, but also in other more low-volume centers that have the expertise to utilize Y-90 in a clinical setting, as well, Salem concludes.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD